Sphere Fluidics Limited Wins $7 Million Investment for Development of Cyto-Mine®

Sphere Fluidics Limited has just secured $7 million in the First Close of its new investment round. The latter will complete shortly with even more funding already in the pipeline.
According to CEO Dr. Frank F. Craig:

Sphere Fluidics Limited has recently successfully developed an alpha-version of its single cell analysis and characterization system (Cyto-Mine® for the biopharmaceutical discovery and development market. We have also convinced several leading biopharmaceutical companies to fund development of this system – indicating the global potential of the product. This new funding will used to develop the manufactured version of Cyto-Mine® (see image below) and enable its commercial launch later this year. This system is transformational for the Biopharmaceutical market.

Click here to view the full press release.